DOSING

TAGRISSO offers convenient, once-daily dosing with or without food1

ONE TABLET ONCE A DAY ONE TABLET ONCE A DAY

One 80-mg tablet, orally,
once a day

WITH OR WITHOUT WITH OR WITHOUT

TAGRISSO tablets may be taken with or without food

OR OR

TAGRISSO can be dissolved into non-carbonated water and swallowed or taken through an NG tube*

  • *

  • TAGRISSO should not be crushed, split or chewed.

  • NG=nasogastric.

Alternate administration options1

  • If the patient is unable to swallow the tablet, the tablet may first be dispersed in 50 mL of non-carbonated water
    • It should be dropped in the water, without crushing, stirred until dispersed and immediately swallowed. An additional half glass of water should be added to ensure that no residue remains and then immediately swallowed
  • If administration via nasogastric tube is required, the same process described for preparing a drinkable solution should be followed, but using volumes of 15 mL for the initial dispersion and 15 mL for the residue rinses

Dosing modifications

Some adverse reactions may require dose interruption, reduction or discontinuation1

Target organ Adverse reaction† Recommended dose modification

Pulmonary

ILD/Pneumonitis

Permanently discontinue TAGRISSO

Cardiac

QTc interval greater than 500 msec on at least 2 separate ECGs

Withhold TAGRISSO until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec, then restart at a reduced dose (40 mg)

QTc interval prolongation with signs/symptoms of serious arrhythmia

Permanently discontinue TAGRISSO

Other

Grade 3 or higher adverse reaction

Withhold TAGRISSO for up to 3 weeks

If Grade 3 or higher adverse reaction improves to Grade 0–2 after withholding of TAGRISSO for up to 3 weeks

TAGRISSO may be restarted at the same dose (80 mg) or a lower dose (40 mg)

Grade 3 or higher adverse reaction that does not improve to Grade 0–2 after withholding for up to 3 weeks

Permanently discontinue TAGRISSO

  • †Note: The intensity of clinical adverse events graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

1L Efficacy 1L Efficacy
Safety Safety

Reference: 1. AstraZeneca Pharmaceuticals. TAGRISSO® (osimertinib). Summary of Product Characteristics, 2020.